TNSN07369A1 - Heteroaryl urea derivatives useful for inhibiting chki - Google Patents

Heteroaryl urea derivatives useful for inhibiting chki

Info

Publication number
TNSN07369A1
TNSN07369A1 TNP2007000369A TNSN07369A TNSN07369A1 TN SN07369 A1 TNSN07369 A1 TN SN07369A1 TN P2007000369 A TNP2007000369 A TN P2007000369A TN SN07369 A TNSN07369 A TN SN07369A TN SN07369 A1 TNSN07369 A1 TN SN07369A1
Authority
TN
Tunisia
Prior art keywords
chki
inhibiting
urea derivatives
derivatives useful
heteroaryl urea
Prior art date
Application number
TNP2007000369A
Other languages
English (en)
Inventor
Frank Diaz
Francine S Farouz
Ryan Holcomb
Edward A Kesicki
Hua Chee Ooi
Alexander Rudolph
Frank Stappenbeck
Eugene Thorsett
John Joseph Gaudino
Kimba L Fisher
Adam Wade Cook
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of TNSN07369A1 publication Critical patent/TNSN07369A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
TNP2007000369A 2005-03-29 2007-09-28 Heteroaryl urea derivatives useful for inhibiting chki TNSN07369A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29
PCT/US2006/011584 WO2006105262A1 (en) 2005-03-29 2006-03-29 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl

Publications (1)

Publication Number Publication Date
TNSN07369A1 true TNSN07369A1 (en) 2008-12-31

Family

ID=36677174

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000369A TNSN07369A1 (en) 2005-03-29 2007-09-28 Heteroaryl urea derivatives useful for inhibiting chki

Country Status (31)

Country Link
US (1) US8093244B2 (cg-RX-API-DMAC7.html)
EP (2) EP1869020B1 (cg-RX-API-DMAC7.html)
JP (2) JP5117374B2 (cg-RX-API-DMAC7.html)
KR (2) KR100912998B1 (cg-RX-API-DMAC7.html)
CN (2) CN102219784A (cg-RX-API-DMAC7.html)
AR (1) AR056645A1 (cg-RX-API-DMAC7.html)
AT (1) ATE490248T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006230337B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0609667A2 (cg-RX-API-DMAC7.html)
CA (1) CA2602199C (cg-RX-API-DMAC7.html)
CR (1) CR9395A (cg-RX-API-DMAC7.html)
CY (1) CY1111240T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006018590D1 (cg-RX-API-DMAC7.html)
DK (1) DK1869020T3 (cg-RX-API-DMAC7.html)
EA (1) EA011287B1 (cg-RX-API-DMAC7.html)
ES (1) ES2356068T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100678T1 (cg-RX-API-DMAC7.html)
IL (1) IL185481A0 (cg-RX-API-DMAC7.html)
MA (1) MA29439B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007012116A (cg-RX-API-DMAC7.html)
NO (1) NO20074944L (cg-RX-API-DMAC7.html)
NZ (1) NZ561458A (cg-RX-API-DMAC7.html)
PL (1) PL1869020T3 (cg-RX-API-DMAC7.html)
PT (1) PT1869020E (cg-RX-API-DMAC7.html)
RS (1) RS51616B (cg-RX-API-DMAC7.html)
SI (1) SI1869020T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07369A1 (cg-RX-API-DMAC7.html)
TW (1) TWI375559B (cg-RX-API-DMAC7.html)
UA (1) UA92164C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006105262A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200707715B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221367A (en) 1988-08-03 1993-06-22 International Business Machines, Corp. Strained defect-free epitaxial mismatched heterostructures and method of fabrication
NZ575394A (en) 2006-10-20 2012-01-12 Icos Corp Compositions of chk1 inhibitors and cyclodextrin
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CA3013514C (en) 2016-02-04 2021-11-23 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
KR20190130621A (ko) * 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers
NL2039212B1 (en) 2024-12-02 2026-06-23 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Mitotic cell phase enrichment and ionizing radiation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
DE69818083T2 (de) 1997-10-06 2004-07-08 Abbott Gmbh & Co. Kg INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057206A2 (en) 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
WO2001062900A1 (en) 2000-02-25 2001-08-30 The Regents Of The University Of California. Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
MXPA03001452A (es) 2000-08-18 2004-05-04 Agouron Pharma Hidroximino-fluorenos heterociclicos y su uso para la inhibicion de las proteinas cinasas.
US20040116497A1 (en) 2001-01-26 2004-06-17 Gabriella Traquandi Chromane derivatives, process for their preparation and their use as antitumor agents
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP2004536113A (ja) 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7166639B2 (en) 2001-10-04 2007-01-23 Smithkline Beecham Corporation NF-κB inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
AU2003224341A1 (en) 2002-04-26 2003-11-10 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
AU2003243318A1 (en) * 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EA009337B1 (ru) 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
AU2005267185A1 (en) * 2004-06-25 2006-02-02 Icos Corporation Bisarylurea derivatives useful for inhibiting CHK1
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Also Published As

Publication number Publication date
PT1869020E (pt) 2010-12-23
ES2356068T3 (es) 2011-04-04
ZA200707715B (en) 2009-09-30
JP2009227682A (ja) 2009-10-08
WO2006105262A1 (en) 2006-10-05
MX2007012116A (es) 2008-04-08
CY1111240T1 (el) 2015-06-11
TWI375559B (en) 2012-11-01
US8093244B2 (en) 2012-01-10
DK1869020T3 (da) 2011-01-24
UA92164C2 (ru) 2010-10-11
TW200722090A (en) 2007-06-16
CN101151259B (zh) 2011-06-15
NZ561458A (en) 2011-03-31
AU2006230337B2 (en) 2011-10-27
HK1119670A1 (en) 2009-03-13
JP2008535830A (ja) 2008-09-04
BRPI0609667A2 (pt) 2010-04-20
CR9395A (es) 2008-03-31
EA200702094A1 (ru) 2008-02-28
EA011287B1 (ru) 2009-02-27
KR20090031459A (ko) 2009-03-25
RS51616B (sr) 2011-08-31
CN102219784A (zh) 2011-10-19
KR20070107178A (ko) 2007-11-06
CA2602199A1 (en) 2006-10-05
US20090143357A1 (en) 2009-06-04
DE602006018590D1 (de) 2011-01-13
EP1869020B1 (en) 2010-12-01
CN101151259A (zh) 2008-03-26
EP1869020A1 (en) 2007-12-26
NO20074944L (no) 2007-10-24
HRP20100678T1 (hr) 2011-02-28
KR100912998B1 (ko) 2009-08-20
IL185481A0 (en) 2008-01-06
ATE490248T1 (de) 2010-12-15
JP5117374B2 (ja) 2013-01-16
AU2006230337A1 (en) 2006-10-05
AR056645A1 (es) 2007-10-17
PL1869020T3 (pl) 2011-05-31
MA29439B1 (fr) 2008-05-02
EP2330105A1 (en) 2011-06-08
CA2602199C (en) 2013-09-10
SI1869020T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
PL364564A1 (en) Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers
NO20074944L (no) Heteroarylureaderivater anvendlige for inhibering av CHK1
WO2009151598A8 (en) Diazacarbazoles and methods of use
WO2009011850A3 (en) Novel therapeutic compounds
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2004108139A8 (en) Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
PL2324008T3 (pl) 3,4-diarylopirazole jako inhibitory kinazy białkowej
TW200606162A (en) Pyrazolopyridine derivatives
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
UA103351C2 (uk) ПОХІДНІ ТІЄНО[3,2-c]ПІРИДИНУ ЯК ІНГІБІТОРИ КІНАЗ ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ РАКУ
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
WO2009030224A3 (de) Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
WO2006021002A3 (en) Compounds useful for inhibiting chk1
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
TW200745102A (en) Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
GB0515025D0 (en) Organic compounds